Providers and researchers at the Adherence 2018 Conference discussed the role of data and surveillance through several approaches and how they are being used to understand local and global epidemics, marshal resources, and mobilize stakeholders for i...
Is Ending the HIV Epidemic Possible, and If So, How? IAPAC Meeting in Geneva Takes Stock of Progress and the Road Ahead
More than 200 health care providers, researchers, and advocates gathered in Geneva, Switzerland, from across the globe to discuss progress and challenges in turning the tide on the HIV epidemic across the globe at the "Controlling the Epidemic" Summi...
This year at CROI 2018 a few studies tried to explore possible mechanisms for the association of increased myocardial infarction risk and abacavir use.
M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy
A retrospective analysis presented at CROI 2018 looked at risk of viral rebound in people who switched to lamivudine (Epivir, 3TC)-based dual antiretroviral therapy.
Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.
Most people who could benefit from pre-exposure prophylaxis are not accessing it, the U.S. Centers for Disease Control and Prevention revealed at this year's Conference on Retroviruses and Opportunistic Infections.
Rob Newells, executive director of the AIDS Project of the East Bay, gives his personal (U.S.-centered, black MSM-focused) highlights from CROI 2018.
Research Is Still Exploring Best Treatment Strategies for Pregnant and Breastfeeding Women, Interactions With Contraceptives
Several new studies presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI) underscore the complex ways that HIV risk and treatment adherence manifest among women of childbearing age.
Researchers at this year's Conference on Retroviruses and Opportunistic Infections (CROI) presented their findings on the ongoing challenges of treating hepatitis C infection among people with HIV.
Reassuring data that the initial loss in bone mineral density during the first year of antiretroviral therapy slowed during subsequent years.